SILVERBACK THERAPEUTICS INC (SBTX) Stock Price, Quote, News and Overview
NASDAQ:SBTX - Nasdaq - US82835W1080 - Common Stock - Currency: USD
SBTX Quote, Performance and Key Statistics
NASDAQ:SBTX (11/8/2022, 4:30:02 PM)
5.87
+0.06 (+1.03%)
The current stock price of SBTX is 5.87 USD. In the past month the price increased by 12.24%. In the past year, price decreased by -30.53%.
SBTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SBTX
Company Profile
Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 90 full-time employees. The company went IPO on 2020-12-04. The firm is focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The Company’s lead virology product candidate, SBT8230, is an ASGR1-TLR8 ImmunoTAC therapeutic. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to a Toll-like receptor 8 (TLR8) linker-payload. SBT8230 is designed to elicit an anti-viral immune response by targeting TLR8 activation to the liver. SBT8230 antibody designed to recognize an epitope distinct from that bound by the ASGR1 ligand, GalNAc, allowing for possible combination of SBT8230. The Company’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites.
Company Info
SILVERBACK THERAPEUTICS INC
500 Fairview Avenue North, Suite 600
Seattle WASHINGTON US
Employees: 90
Company Website: https://silverbacktx.com/
Phone: 12064562900.0
SILVERBACK THERAPEUTICS INC / SBTX FAQ
What is the stock price of SILVERBACK THERAPEUTICS INC today?
The current stock price of SBTX is 5.87 USD. The price increased by 1.03% in the last trading session.
What is the ticker symbol for SILVERBACK THERAPEUTICS INC stock?
The exchange symbol of SILVERBACK THERAPEUTICS INC is SBTX and it is listed on the Nasdaq exchange.
On which exchange is SBTX stock listed?
SBTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SILVERBACK THERAPEUTICS INC stock?
6 analysts have analysed SBTX and the average price target is 5.1 USD. This implies a price decrease of -13.12% is expected in the next year compared to the current price of 5.87. Check the SILVERBACK THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SILVERBACK THERAPEUTICS INC worth?
SILVERBACK THERAPEUTICS INC (SBTX) has a market capitalization of 210.63M USD. This makes SBTX a Micro Cap stock.
How many employees does SILVERBACK THERAPEUTICS INC have?
SILVERBACK THERAPEUTICS INC (SBTX) currently has 90 employees.
What are the support and resistance levels for SILVERBACK THERAPEUTICS INC (SBTX) stock?
SILVERBACK THERAPEUTICS INC (SBTX) has a support level at 5.57 and a resistance level at 6.15. Check the full technical report for a detailed analysis of SBTX support and resistance levels.
Should I buy SILVERBACK THERAPEUTICS INC (SBTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SBTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SBTX, evaluating the profitability, health, valuation and growth aspects
- SILVERBACK THERAPEUTICS INC (SBTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SILVERBACK THERAPEUTICS INC (SBTX) Sales and EPS estimates to see what analysts future expectations are.
- SILVERBACK THERAPEUTICS INC (SBTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SILVERBACK THERAPEUTICS INC (SBTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SILVERBACK THERAPEUTICS INC (SBTX) Stock Chart to make your own analysis
- SILVERBACK THERAPEUTICS INC (SBTX) Latest news and press-releases to stay up to date.
Does SILVERBACK THERAPEUTICS INC (SBTX) stock pay dividends?
SBTX does not pay a dividend.
When does SILVERBACK THERAPEUTICS INC (SBTX) report earnings?
SILVERBACK THERAPEUTICS INC (SBTX) will report earnings on 2022-11-22, after the market close.
What is the Price/Earnings (PE) ratio of SILVERBACK THERAPEUTICS INC (SBTX)?
SILVERBACK THERAPEUTICS INC (SBTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.56).
SBTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SBTX. When comparing the yearly performance of all stocks, SBTX turns out to be only a medium performer in the overall market: it outperformed 62.07% of all stocks.
SBTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SBTX. No worries on liquidiy or solvency for SBTX as it has an excellent financial health rating, but there are worries on the profitability.
SBTX Financial Highlights
Over the last trailing twelve months SBTX reported a non-GAAP Earnings per Share(EPS) of -2.56. The EPS decreased by -6.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.5% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
SBTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to SBTX. The Buy consensus is the average rating of analysts ratings from 6 analysts.